http://orcid.org/0000-0003-1164-6088
References
- Mugii N, Hasewaga M, Matsushita T, et al. Oropharyngeal dysphasia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One. 2016;11:e0154746.
- Parodi A, Caproni M, Marzano AV, et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol. 2002;82:48–51.
- Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review. Clinic Rev Allerg Immunol. 2016;51:293–302.
- Langdon CP, Mulcahy K, Shepherd KL, et al. Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature. Dysphagia. 2012;27:408–417.
- Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513–522.
- Palace J, Losseff N, Clough C. Isolated dysphagia due to polymyositis. Muscle Nerve. 1993;16:680–681.
- Mii S, Niiyama S, Kusunoki M, et al. Cyclosporine A as treatment of esophageal involvement in dermatomyositis. Rheumatol Int. 2006;27:183–185.
- Hirano F, Tanaka H, Nomura Y, et al. Successful treatment of refractory polymyositis with pulse intravenous cyclophosphamide and low-dose weekly oral methotrexate therapy. Intern Med. 1993;32:749–752.
- Marie I, Menard JF, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62:1748–1755.
- Nagano H, Yoshifuku K, Kurono Y. Polymyositis with dysphagia treated with endoscopic balloon dilatation. Auris Nasus Larynx. 2009;36:705–708.
- Yabunaka K, Konishi H, Nakagami G, et al. Video uoroscopy-guided balloon dilatation for treatment of severe pharyngeal dysphagia. Diagn Interv Radiol. 2015;21:173–176.